{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:11:14Z","timestamp":1778155874618,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants and young children. Broad immunization with the monoclonal antibody nirsevimab represents a promising preventive strategy. However, real-world data on its impact at the population level remain limited, particularly in routine clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center study evaluated a cohort of 261 children under two years of age hospitalized with RSV across three seasons (2018\u20132019, 2023\u20132024, 2024\u20132025) at a Berlin tertiary care hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analyzed admissions and clinical courses of RSV-associated hospitalizations in children\u2009&lt;\u20092 years of age at a large tertiary care center in Germany between 2018 and 2025. Following the nationwide introduction of nirsevimab in 2024, the number of RSV-related hospitalizations in our center decreased by 51% compared to the previous season. During the 2024\/2025 season 90.2% of hospitalized patients had not received nirsevimab immunization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The introduction of nirsevimab was associated with a substantial reduction in RSV-related hospitalizations in infants and young children in a real-world clinical setting. These findings support a beneficial role of passive immunization with nirsevimab and highlight its potential to reduce RSV-related disease burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40348-026-00232-5","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:21:55Z","timestamp":1778152915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center"],"prefix":"10.1186","volume":"13","author":[{"given":"Moritz","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst von","family":"Bernuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Thee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"10098","key":"232_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi T et al (2017) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390(10098):946\u2013958","journal-title":"Lancet"},{"issue":"11","key":"232_CR2","doi-asserted-by":"publisher","first-page":"e13211","DOI":"10.1111\/irv.13211","volume":"17","author":"M Wick","year":"2023","unstructured":"Wick M et al (2023) Inpatient burden of respiratory syncytial virus in children\u2009\u2264\u20092 years of age in Germany: a retrospective analysis of nationwide hospitalization data, 2019\u20132022. Influenza Other Respir Viruses 17(11):e13211","journal-title":"Influenza Other Respir Viruses"},{"issue":"9","key":"232_CR3","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1128\/AAC.06446-11","volume":"56","author":"GJ Robbie","year":"2012","unstructured":"Robbie GJ et al (2012) Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 56(9):4927\u20134936","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"232_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/jac\/dkad076","volume":"78","author":"SCJ Jorgensen","year":"2023","unstructured":"Jorgensen SCJ (2023) Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. J Antimicrob Chemother 78(5):1143\u20131149","journal-title":"J Antimicrob Chemother"},{"key":"232_CR5","first-page":"1","volume":"26","author":"St\u00e4ndige Impfkommission (STIKO)","year":"2024","unstructured":"St\u00e4ndige Impfkommission (STIKO) (2024) Beschluss und wissenschaftliche Begr\u00fcndung zur Empfehlung der STIKO zur spezifischen Prophylaxe von RSV-Erkrankungen mit Nirsevimab bei Neugeborenen und S\u00e4uglingen in ihrer ersten RSV-Saison. Epidemiol Bull 26:1\u201314","journal-title":"Epidemiol Bull"},{"issue":"17","key":"232_CR6","first-page":"472","volume":"122","author":"V Sch\u00f6nfeld","year":"2025","unstructured":"Sch\u00f6nfeld V et al (2025) Inzidenz von RSV-Infektionen nach Einf\u00fchrung der Prophylaxe mit monoklonalen Antik\u00f6rpern. Dtsch Arztebl Int 122(17):472\u2013473","journal-title":"Dtsch Arztebl Int"},{"key":"232_CR7","unstructured":"Landesamtf\u00fcr Gesundheit und Soziales Berlin (LAGeSo) (2025). Wochen\u00fcbersicht \u00fcber die im Land Berlin gem\u00e4\u00df Infektionsschutzgesetz (IfSG) erfassten Infektionskrankheiten \u2013 20. Meldewoche 2025. LAGeSo, Berlin https:\/\/data.lageso.de\/lageso\/infektionsschutz\/wochenbericht\/2025\/EWU_20-2025.pdf"},{"issue":"11","key":"232_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00431-025-06588-6","volume":"184","author":"F Nieddu","year":"2025","unstructured":"Nieddu F et al (2025) Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024-25 RSV season. Eur J Pediatr 184(11):728. https:\/\/doi.org\/10.1007\/s00431-025-06588-6","journal-title":"Eur J Pediatr"},{"key":"232_CR9","doi-asserted-by":"publisher","first-page":"127716","DOI":"10.1016\/j.vaccine.2025.127716","volume":"64","author":"M Wetzke","year":"2025","unstructured":"Wetzke M et al (2025) Immunization acceptance after broad recommendation for RSV prophylaxis: results from a cross-sectional study in Germany. Vaccine 64:127716","journal-title":"Vaccine"},{"key":"232_CR10","unstructured":"Landesamtf\u00fcr Gesundheit und Soziales Berlin (LAGeSo) (2025). Wochen\u00fcbersicht \u00fcber die im Land Berlin gem\u00e4\u00df Infektionsschutzgesetz (IfSG) erfassten Infektionskrankheiten \u2013 50. Meldewoche 2025. LAGeSo, Berlin https:\/\/data.lageso.de\/lageso\/infektionsschutz\/wochenbericht\/2025\/EWU_50-2025.pdf"},{"issue":"6","key":"232_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","volume":"9","author":"APS Munro","year":"2025","unstructured":"Munro APS et al (2025) 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc Health 9(6):404\u2013412","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00232-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-026-00232-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00232-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:22:03Z","timestamp":1778152923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40348-026-00232-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1186\/s40348-026-00232-5","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study analyzed routinely collected, anonymized clinical data of children hospitalized with RSV infection at a university hospital. According to local regulations, ethical approval was not required for this type of secondary data analysis. Study information was provided via public notice (opt-out procedure), and no objections were raised.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}